Study of Prednisone, Vinblastine, Doxorubicin, and Gemcitabine in Elderly Patients With Advanced Stages Hodgkin's Lymphoma
NCT ID: NCT00147875
Last Updated: 2009-09-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1/PHASE2
60 participants
INTERVENTIONAL
2004-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
PVAG-14 Pilot for Intermediate Stages Hodgkin Lymphoma
NCT00512980
A Phase II Study VEPEMB In Patients With Hodgkin's Lymphoma Aged ≥ 60 Years
NCT00079105
Doxorubicin Hydrochloride, Pembrolizumab, Vinblastine, and Dacarbazine in Treating Patients With Classical Hodgkin Lymphoma
NCT03331341
Combination Chemotherapy in Treating Older Patients With Non-Hodgkin's Lymphoma
NCT00039351
Prospective Study on HIV-related Hodgkin Lymphoma
NCT01468740
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Prednisone
Vinblastine
Doxorubicin (Adriamycin)
Gemcitabine
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Clinical stage IIB (with risk factors bulky mediastinal mass and/or extranodal involvement), III, or IV
* No prior antitumor therapy
* Age 60 to 75 years
* WHO performance status 0-2
* Normal pulmonary function
* Written informed consent
Exclusion Criteria
* Leukocytes \< 2,500/microL
* Platelets \< 100,000/microL
60 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
German Hodgkin's Lymphoma Study Group
OTHER
Eli Lilly and Company
INDUSTRY
University of Cologne
OTHER
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Andreas Engert
Role: PRINCIPAL_INVESTIGATOR
University of Cologne
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Cologne
Cologne, North Rhine-Westphalia, Germany
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Boll B, Bredenfeld H, Gorgen H, Halbsguth T, Eich HT, Soekler M, Markova J, Keller U, Graeven U, Kremers S, Geissler M, Trenn G, Fuchs M, von Tresckow B, Eichenauer DA, Borchmann P, Engert A. Phase 2 study of PVAG (prednisone, vinblastine, doxorubicin, gemcitabine) in elderly patients with early unfavorable or advanced stage Hodgkin lymphoma. Blood. 2011 Dec 8;118(24):6292-8. doi: 10.1182/blood-2011-07-368167. Epub 2011 Sep 13.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PVAG elderly
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.